Tenders Are Invited For Conclusion Of A Non-Exclusive Discount Agreement According To § 130A Paragraph 8 Sgb ... in Germany

Work Detail

Conclusion Of A Non-Exclusive Discount Agreement According To § 130A Paragraph 8 Sgb V For The Active Ingredient Rituximab, Atc L01af01 For The Period August 1St, 2023 - July 31St, 2025. § 130A Paragraph 8 Sgb V Enables The Health Insurance Companies And Pharmaceutical Companies To Conclude Framework Discount Agreements For The Drugs To Be Supplied At The Expense Of The Statutory Health Insurance Companies. With Regard To The Relevant Legal Regulations For The Award Of Public Contracts, A Regular Process Of Active Ingredient-Related, Formal Award Procedures Takes Place According To The Regulations Of The 4Th Part Of The Gwb By Dak-Gesundheit. For Pharmaceuticals To Be Specified By The Bidder In Annex 2 To The Contract For The Above-Mentioned For The Active Ingredient Rituximab, Atc L01af01, Dakgeundheit Intends To Conclude Drug Discount Agreements With As Many Interested Pharmaceutical Companies As Possible Before New Drug Discount Agreements Come Into Force. Arge Rituximab Iii Intends To Conclude General Drug Discount Agreements For The Above-Mentioned Active Substance With As Many Pharmaceutical Companies As Possible, At Least With All Interested Ones. The Following Health Insurance Companies Belong To The Arge Rituximab Iii: Dak Health Technicians Health Insurance Commercial Health Insurance Hek Hanseatic Health Insurance Hkk Commercial Health Insurance Together Hereinafter Referred To As Health Insurance Companies. A Discount Agreement In The Context Of The Admission Model For The Above The Active Substance Comes Into Force For The First Time On 08/01/2023 And Ends On 07/31/2025. Irrespective Of This, It Ends Automatically When The Exclusive Contract Comes Into Force.

Contact Information